Results 61 to 70 of about 4,421 (195)
JIMD Reports, Volume 67, Issue 5, September 2026.ABSTRACT Fructose‐1,6‐bisphosphatase deficiency is a rare inherited metabolic disorder of gluconeogenesis characterized by recurrent hypoglycemia and lactic acidosis, typically triggered by inadequate glucose intake or increased consumption of fructose, sucrose, or sorbitol.
Raashda A. Sulaiman +6 more
wiley +1 more source
From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity
Obesity, Volume 34, Issue 9, Page 1708-1717, September 2026.ABSTRACT An international panel of experts from the U.S. and China convened to discuss the 2026 TOS–OMA–OAC Expert Guidance Statement on the Pharmacological Management of Obesity, focusing on emerging evidence, regional considerations, and challenges in translating recommendations into long‐term care.
Hong Chen +5 more
wiley +1 more source
Pregnancy outcomes in women with type 1 diabetes using insulin degludec
, 2022 Aims: To evaluate pregnancy outcomes in a real-world setting of pregnant women with type 1 diabetes using the ultra-long-acting insulin analog degludec compared to other long-acting insulin analogs throughout pregnancy.
Damm, Peter +3 more
core +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Basal insulin have been developed over the years. In recent times newer analogues have been added to the armanentarium for diabetes therapy.
S V Madhu, M Velmurugan
doaj +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock +5 more
wiley +1 more source
Modern basal insulin analogs: An incomplete story
Indian Journal of Endocrinology and Metabolism, 2014 The currently available basal insulin does not completely mimic the endogenous insulin secretion. This has continued to promote the search for ideal basal insulin.
Awadhesh Kumar Singh +1 more
doaj +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7705-7718, September 2026.ABSTRACT Gestational diabetes mellitus (GDM) represents far more than a transient glycaemic disorder: it is a sentinel metabolic event that unveils pre‐existing defects in β‐cell function and insulin action, with profound implications for both maternal and offspring cardiometabolic health across the lifespan.
Mustafa Kanat +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8515-8522, September 2026.ABSTRACT Aims To investigate the efficacy and safety of intensifying once‐weekly insulin icodec (icodec) with once‐weekly semaglutide in adults with type 2 diabetes (T2D). Materials and Methods ONWARDS 8 was a single‐arm, open‐label, treat‐to‐target, Phase 3b trial comprising a 26‐week icodec run‐in period and a 26‐week semaglutide intensification ...
Krzysztof Strojek +5 more
wiley +1 more source
Effect of tirzepatide vs insulin (insulin degludec and insulin glargine) on body weight.
, 2023 Effect of tirzepatide vs insulin (insulin degludec and insulin glargine) on body weight.
Bin Yu (14464) +8 more
core +1 more source
Journal of DiabetologyIntroduction: Insulin degludec is an ultra-long-acting basal insulin characterized by low day-to-day variability compared to first-generation basal insulins.
Rutul Gokalani +10 more
doaj +1 more source